INNV · CIK 1834376
What InnovAge Holding Corp. told the SEC could break it.
InnovAge's defining exposure is its near-total dependence on a single government program: PACE accounted for 99.8% of its revenue (roughly 55% Medicaid, 45% Medicare), so its operations hinge on government funding levels and PACE rules, and any rate cut or rule change would be materially adverse. That risk is geographically concentrated, since it operates in only six states with a significant share of operations in Colorado, leaving it especially exposed to that state's budget and regulatory decisions. Reimbursement pressure is already visible — a 2% Medicare sequestration (extended through 2032) reduces PACE payments, and IRA drug-pricing changes may affect its prescription-drug costs. It also flags a $27.0 million securities class-action settlement reached in June 2025.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- 99.8% revenue from the government PACE programhigh
InnovAge derives 99.8% of revenue from the PACE program (Medicaid 55% / Medicare 45%), making it almost entirely dependent on government funding levels and PACE program rules; rate cuts or rule changes would be materially adverse.
“We receive nearly all of our revenue through the PACE program, which accounted for 99.8% of our revenue for each of the years ended June 30, 2025 and 2024. As a result, our operations are dependent on government funding levels for PACE programs.”
SEC filing →As of 2025 - Medicare sequestration & IRA drug-pricing affecting PACEmedium
A 2% Medicare sequestration (extended through FY2032) reduces payments to PACE organizations, and IRA Medicare drug-pricing changes may affect PACE prescription-drug costs and reimbursement.
“reduce all Medicare payments, including payments to PACE organizations, by two percent per year beginning on April 1, 2013.”
Geographic concentration
- six states; significant operations concentrated in Coloradomedium
InnovAge operates in only six states (CA, CO, FL, NM, PA, VA) with a significant percentage of operations in Colorado, making it especially exposed to that state's budget appropriations and regulatory developments.
“Our presence is currently limited to six states, with a significant percentage of our operations in the State of Colorado.”
SEC filing →As of 2025
Litigation
- $27.0M securities class-action settlementmedium
In June 2025 InnovAge agreed to a $27.0M settlement of a securities class-action alleging Securities Act/Exchange Act violations; litigation costs remain significant.
“in June 2025, the Company and the other defendants entered into a settlement agreement to resolve the securities class action lawsuit with plaintiffs who alleged violations of the Securities Act and the Exchange Act in exchange for a payment by the Company of $27.0 million”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Tabula Rasa HealthCare Group, Inc. (TRHC)
“Pursuant to a Management Services Agreement, TRHC provides management services to our acquired pharmacy business with an initial term of five years.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch